Johnson & Johnson will buy medtech maker Abiomed in a $16.6 billion deal

JNJ says it’s looking to strengthen its position as a solutions provider for the world’s top cause of death—cardiovascular disease.

Johnson & Johnson has announced that it is acquiring the Danvers, Massachusetts-based medical technology company Abiomed for $16.6 billion. Here’s what you need to know:

Read Full Story